PTI 80

Drug Profile

PTI 80

Alternative Names: Exebryl-1®; PTI-80

Latest Information Update: 26 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ProteoTech
  • Class Nootropics; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 26 May 2016 This programme is still active
  • 31 May 2012 Tianjin Tasly Pharmaceutical is now called Tasly Pharmaceutical Group
  • 06 Oct 2010 ProteoTech and Tianjin Tasly Pharmaceutical agree to co-develop Exebryl-1® in China and the US for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top